Screener
Discontinued — last reported Q2 '26
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Elanco Animal Health Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Elanco Animal Health Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001739104-26-000043
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenue | $1,368 | $1,241 | $2,739 | $2,434 |
| Cost of sales | 570 | 528 | 1,156 | 1,037 |
| Gross profit | 798 | 713 | 1,583 | 1,397 |
| Research and development | 92 | 92 | 189 | 186 |
| Marketing, selling and administrative | 449 | 400 | 830 | 741 |
| Amortization of intangible assets | 139 | 136 | 277 | 264 |
| Asset impairment, restructuring and other special charges | 9 | 1 | 25 | 10 |
| Interest expense, net of capitalized interest | 59 | 48 | 116 | 88 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Elanco Animal Health Inc.'s R&D?
- Elanco Animal Health Inc. (ELAN) reported R&D of $92M in Q2 2026.
- How has Elanco Animal Health Inc.'s R&D changed year-over-year?
- Elanco Animal Health Inc.'s R&D decreased by 0.0% year-over-year, from $92M to $92M.
- What is the long-term trend for Elanco Animal Health Inc.'s R&D?
- Over 4 years (2021 to 2025), Elanco Animal Health Inc.'s R&D has grown at a -0.1% compound annual growth rate (CAGR), from $369M to $368M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Elanco Animal Health Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude